Written questions, answers and statements

Hormone Replacement Therapy

Show full question

Question for Department of Health and Social Care

UIN 50771, tabled on 7 May 2025

Question

Freddie van Mierlo
Liberal Democrat
Henley and Thame
Commons

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 March 2025 to Question 35541 on Hormone Replacement Therapy, what discussions he has had with the Medicines and Healthcare products Regulatory Agency on the adequacy of the process for applying for UK licenses for HRT implant manufacturers.

Answer

Karin Smyth
Labour
Bristol South
Commons

Answered on

12 May 2025

The processes of the Medicines and Healthcare products Regulatory Agency (MHRA) are now performing within the expected timelines, and are meeting company commitments. Guidance has been updated on 3 April 2024 to aid the rapid approval of medicines, ensuring that quality, safety, and efficacy assessments are completed.

The assessment of hormone replacement therapy products falls within these overall processes, and we are working closely with Department’s medicines supply to ensure the early flagging of issues, so they can be resolved by either companies or the MHRA.

Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.